Abstract
The immune system protects organisms from pathogens. The immune cells, in particular T- and B-lymphocytes, develop and acquire effector functions in specialized tissues called the lymphoid organs. The lymphoid organs exhibit lower oxygen tensions than the blood or the atmosphere. Furthermore, inflammatory and tumor environments where lymphocytes execute effector functions also have very low oxygen tensions. These findings led to the hypothesis that lymphocytes may have evolved adaptive mechanisms to function under hypoxic conditions. Cellular responses to hypoxia are triggered by the hypoxia inducible factor-1α (HIF-1α). In this paper we review the development and function of T- and B-lymphocytes in the absence HIF-1a. Our studies suggest that HIF-1α deficiency depresses the function of cytotoxic T-lymphocytes and blocks B-cell development in the bone marrow. B1 lymphocytes of fetal origin, on the other hand, accumulate and may produce auto-antibodies and autoimmunity.
Keywords: hif-, t-lymphocyte, b-lymphocyte, lymphocyte development
Current Pharmaceutical Design
Title: HIF-1α Deficiency Perturbs T and B Cell Functions
Volume: 9 Issue: 23
Author(s): Hidefumi Kojima, Michail V. Sitkovsky and Marilia Cascalho
Affiliation:
Keywords: hif-, t-lymphocyte, b-lymphocyte, lymphocyte development
Abstract: The immune system protects organisms from pathogens. The immune cells, in particular T- and B-lymphocytes, develop and acquire effector functions in specialized tissues called the lymphoid organs. The lymphoid organs exhibit lower oxygen tensions than the blood or the atmosphere. Furthermore, inflammatory and tumor environments where lymphocytes execute effector functions also have very low oxygen tensions. These findings led to the hypothesis that lymphocytes may have evolved adaptive mechanisms to function under hypoxic conditions. Cellular responses to hypoxia are triggered by the hypoxia inducible factor-1α (HIF-1α). In this paper we review the development and function of T- and B-lymphocytes in the absence HIF-1a. Our studies suggest that HIF-1α deficiency depresses the function of cytotoxic T-lymphocytes and blocks B-cell development in the bone marrow. B1 lymphocytes of fetal origin, on the other hand, accumulate and may produce auto-antibodies and autoimmunity.
Export Options
About this article
Cite this article as:
Kojima Hidefumi, Sitkovsky V. Michail and Cascalho Marilia, HIF-1α Deficiency Perturbs T and B Cell Functions, Current Pharmaceutical Design 2003; 9 (23) . https://dx.doi.org/10.2174/1381612033454388
DOI https://dx.doi.org/10.2174/1381612033454388 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Morpho-Functional Features of In-Vitro Cell Death Induced by Physical Agents
Current Pharmaceutical Design Patent Selections
Recent Patents on Anti-Infective Drug Discovery Phosphoinositide-3-kinases as the Novel Therapeutic Targets for the Inflammatory Diseases: Current and Future Perspectives
Current Drug Targets Survivin Modulators: An Updated Patent Review (2011 - 2015)
Recent Patents on Anti-Cancer Drug Discovery Pyrrolo[2,1-c][1,4]benzodiazepine as a Scaffold for the Design and Synthesis of Anti- Tumour Drugs
Anti-Cancer Agents in Medicinal Chemistry Signal Transduction Therapy for Cancer - Whither Now?
Current Signal Transduction Therapy Gene Therapeutic Approaches for Immune Modulation in AIDS
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Adhesion Dependent Signalling in the Tumour Microenvironment: The Future of Drug Targetting
Current Pharmaceutical Design Drug Treatment of Obesity: Established and Emerging Therapies
Mini-Reviews in Medicinal Chemistry In Silico Identification and Analysis of Drug Resistant Mutants of ABL Tyrosine Kinase Based on Detrimental Missense Mutations
Current Signal Transduction Therapy SRLVs: A Genetic Continuum of Lentiviral Species in Sheep and Goats with Cumulative Evidence of Cross Species Transmission
Current HIV Research Randomised Trials of Graft Versus Host Disease Prophylaxis in Haemopoietic Stem Cell Transplantation
Reviews on Recent Clinical Trials Medical and Dental Implications of Down Syndrome: A Review Part 1: General and Craniofacial Characteristic
Applied Clinical Research, Clinical Trials and Regulatory Affairs The Role of Bax/Bcl-2 and Pro-Caspase Peptides in Hypoxia/Reperfusion-Dependent Regulation of MAPKERK: Discordant Proteomic Effect of MAPKp38
Protein & Peptide Letters P-Glycoprotein Mediated Multidrug Resistance Reversal by Phytochemicals: A Review of SAR & Future Perspective for Drug Design
Current Topics in Medicinal Chemistry Interaction of Biologically Active Amines with Mitochondria and Their Role in the Mitochondrial-Mediated Pathway of Apoptosis
Current Medicinal Chemistry Thermodynamics and Electro-Biologic Prospects for Therapies to Intervene in Cancer Progression
Current Cancer Therapy Reviews Flavonoids in Cancer Prevention
Anti-Cancer Agents in Medicinal Chemistry Herpes Simplex Virus Type 1 Amplicons and their Hybrid Virus Partners, EBV, AAV, and Retrovirus
Current Gene Therapy The Function and Regulation of BMP6 in Various Kinds of Stem Cells
Current Pharmaceutical Design